Drug Information

Drug General Information
Drug ID
D0R5WX
Former ID
DNC004820
Drug Name
4-Benzyl-1-chroman-2-ylmethyl-piperidine
Drug Type
Small molecular drug
Indication Discovery agent Investigative [527368]
Formula
C22H27NO
Canonical SMILES
C1CC2=CC=CC=C2OC1CN3CCC(CC3)CC4=CC=CC=C4
InChI
1S/C22H27NO/c1-2-6-18(7-3-1)16-19-12-14-23(15-13-19)17-21-11-10-20-8-4-5-9-22(20)24-21/h1-9,19,21H,10-17H2
InChIKey
XIEPNNMDKPLLAY-UHFFFAOYSA-N
PubChem Compound ID
11220953
Target and Pathway
Target(s) D(2) dopamine receptor Target Info Inhibitor [527368]
5-hydroxytryptamine 1A receptor Target Info Inhibitor [527368]
KEGG Pathway Rap1 signaling pathway
cAMP signaling pathway
Neuroactive ligand-receptor interaction
Gap junction
Dopaminergic synapse
Parkinson's disease
Cocaine addiction
Alcoholismhsa04024:cAMP signaling pathway
Serotonergic synapse
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Dopamine receptor mediated signaling pathway
Nicotine pharmacodynamics pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
5HT1 type receptor mediated signaling pathway
Reactome Dopamine receptors
G alpha (i) signalling eventsR-HSA-390666:Serotonin receptors
G alpha (i) signalling events
WikiPathways Hypothetical Network for Drug Addiction
Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
Genes and (Common) Pathways Underlying Drug Addiction
GPCR ligand binding
GPCR downstream signaling
Nicotine Activity on Dopaminergic NeuronsWP722:Serotonin HTR1 Group and FOS Pathway
SIDS Susceptibility Pathways
References
Ref 527368J Med Chem. 2005 Jan 13;48(1):266-73.Synthesis and structure-activity relationships of 1-aralkyl-4-benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent sigma ligands.
Ref 527368J Med Chem. 2005 Jan 13;48(1):266-73.Synthesis and structure-activity relationships of 1-aralkyl-4-benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent sigma ligands.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.